Literature DB >> 17261429

Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis.

Vera Krane1, Detlef H Krieter, Manfred Olschewski, Winfried März, Johannes F E Mann, Eberhard Ritz, Christoph Wanner.   

Abstract

BACKGROUND: Effects of dialyzer membrane characteristics on morbidity and mortality are highly controversial.
METHODS: Post hoc, we analyzed data from the German Diabetes and Dialysis Study that evaluated atorvastatin in high-risk patients. Four groups were identified being constantly dialyzed with high-flux synthetic (n = 241), low-flux synthetic (n = 247), low-flux semisynthetic (n = 119), or cellulosic low-flux membranes (n = 41). Two end points were investigated: (1) a cardiovascular end point consisting of cardiac death, nonfatal myocardial infarction, and stroke and (2) death.
RESULTS: After 4 years of follow-up, adjusted multivariate relative risks (RRs) were calculated. The RR to reach a cardiovascular end point was greater for patients dialyzed with cellulosic low-flux (RR, 2.33; 95% confidence interval [CI], 1.38 to 3.94; P = 0.002), low-flux semisynthetic (RR, 1.92; 95% CI, 1.35 to 2.73; P = 0.0003), or low-flux synthetic membranes (RR, 1.35; 95% CI, 0.99 to 1.85; P = 0.06) than for those treated with high-flux synthetic dialyzers. The likelihood to die was greater with cellulosic low-flux (RR, 4.14; 95% CI, 2.79 to 6.15; P < 0.0001), low-flux semisynthetic (RR, 2.24; 95% CI, 1.66 to 3.02; P < 0.0001), and low-flux synthetic membranes (RR, 1.59; 95% CI, 1.22 to 2.07; P = 0.0006) than with high-flux synthetic membranes. With respect to low-flux synthetic membranes, RRs of mortality for patients using cellulosic low-flux and low-flux semisynthetic membranes were 161% (RR, 2.61; 95 % CI, 1.80 to 3.79; P < 0.0001) and 41% (RR, 1.41; 95% CI, 1.07 to 1.86; P = 0.016) greater. Cellulosic low-flux membrane use was associated with an 85% (RR, 1.85; 95% CI, 1.24 to 2.76; P = 0.0025) greater RR of death than low-flux semisynthetic membranes.
CONCLUSION: These data suggest that biocompatibility and permeability may impact on death and cardiovascular events in hemodialysis patients with type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261429     DOI: 10.1053/j.ajkd.2006.11.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  17 in total

1.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

2.  Association between N-terminal pro-brain natriuretic peptide and acute ischemic stroke in patients on chronic hemodialysis.

Authors:  Yong Kyun Kim; Seok Joon Shin; Sang-Hyun Ihm; Chan Seok Park; Hee-Yeol Kim; Young-Du Kim; Dong Suk Shim; Ho Cheol Song; Chul Woo Yang; Yong-Soo Kim; Euy Jin Choi
Journal:  Int Urol Nephrol       Date:  2009-12-29       Impact factor: 2.370

Review 3.  Home haemodialysis and uraemic toxin removal: does a happy marriage exist?

Authors:  Raymond Vanholder; Sunny Eloot; Nathalie Neirynck; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

4.  The impact of membrane permeability and dialysate purity on cardiovascular outcomes.

Authors:  Gulay Asci; Huseyin Tz; Mehmet Ozkahya; Soner Duman; Meltem Sezis Demirci; Mustafa Cirit; Savas Sipahi; Hamad Dheir; Devrim Bozkurt; Fatih Kircelli; Ebru Sevinc Ok; Sinan Erten; Muhittin Ertilav; Timur Kose; Ali Basci; Jochen G Raimann; Nathan W Levin; Ercan Ok
Journal:  J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 10.121

Review 5.  An update on uremic toxins.

Authors:  N Neirynck; R Vanholder; E Schepers; S Eloot; A Pletinck; G Glorieux
Journal:  Int Urol Nephrol       Date:  2012-08-15       Impact factor: 2.370

6.  Effect of membrane permeability on survival of hemodialysis patients.

Authors:  Francesco Locatelli; Alejandro Martin-Malo; Thierry Hannedouche; Alfredo Loureiro; Menelaos Papadimitriou; Volker Wizemann; Stefan H Jacobson; Stanislaw Czekalski; Claudio Ronco; Raymond Vanholder
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

7.  Dialyzer Reuse and Outcomes of High Flux Dialysis.

Authors:  Christos Argyropoulos; Maria-Eleni Roumelioti; Abdus Sattar; John A Kellum; Lisa Weissfeld; Mark L Unruh
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

Review 8.  Prognostic effect of high-flux hemodialysis in patients with chronic kidney disease.

Authors:  X Li; H Xu; X C Xiao; S L Deng; W Wang; R Tang
Journal:  Braz J Med Biol Res       Date:  2015-11-27       Impact factor: 2.590

9.  Comparison of the impact of high-flux dialysis on mortality in hemodialysis patients with and without residual renal function.

Authors:  Hyung Wook Kim; Su-Hyun Kim; Young Ok Kim; Dong Chan Jin; Ho Chul Song; Euy Jin Choi; Yong-Lim Kim; Yon-Su Kim; Shin-Wook Kang; Nam-Ho Kim; Chul Woo Yang; Yong Kyun Kim
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

Review 10.  What is new in uremic toxicity?

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux
Journal:  Pediatr Nephrol       Date:  2008-03-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.